ZIRDOSE-CP Study of TLX250-CDx published in EJNMMI Research: Confirms Favorable Safety and Tolerability Profile in Chinese patients

Telix today announces that final results from the ZIRDOSE-CP Phase 1 study of TLX250-CDx (Zircaix®, 89Zr-girentuximab) PET imaging in Chinese patients with suspected clear cell renal cell carcinoma (ccRCC) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Research.

Read more

Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference

Telix today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.). 

Read more

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

Telix today provides a precision medicine portfolio update in relation to

Read more

ProstACT Global Study: Status

Telix today provides an update to confirm the current status of the ProstACT Global Phase 3 study of its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC). This announcement is provided in response to inaccurate information in market circulation.

Read more

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

Telix today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise.

Read more

Telix Announces Record-Breaking Presence at EANM 2025

Telix today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Barcelona from 4 – 8 October 2025.

Read more

CMS Grants Transitional Pass-Through Status for Gozellix

Telix today announces that the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging agent for prostate cancer.

Read more

Telix and FDA Agree on Resubmission Pathway for TLX101-CDx (Pixclara®) U.S. NDA

Telix today announces that it has reached agreement with the United States (U.S.) Food and Drug Administration (FDA) regarding resubmission of its New Drug Application (NDA) for TLX101-CDx (Floretyrosine F18 or 18F-FET, Pixclara®), an investigational agent for the imaging of glioma, a rare and life-threatening brain cancer. As previously advised, the Company confirms its plan to resubmit the NDA during Q4 2025.

Read more

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.

Read more

Telix H1 2025 Results: Investor Webcast Notification

Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.

Read more